Renalytix plc
(“Renalytix” or the “Company”)
Notice of 2026 Annual General Meeting
LONDON and NEW YORK, 18 November 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, confirms that the AGM of the Company will be held at 16 Columbus Walk, Brigantine Place, Cardiff, CF10 4BY on Friday 11 December 2026 at 10:30 a.m. (GMT).
The full Notice of AGM has been posted to shareholders who have not consented to receive electronic communications and is available on the Company website here: https://investors.renalytix.com/documents/.
As announced on 14 September 2026, the Company has extended its accounting reference date to 31 December 2026. As a result, the Company will publish audited accounts for the 18 month period ending 31 December 2026 by 30 June 2027, at which time an Annual General Meeting will be convened to lay them before shareholders.
For further information, please contact:
Renalytix plc |
||
James McCullough, CEO |
Via Walbrook PR | |
|
| |
SP Angel Corporate Finance LLP (Nominated Adviser, Joint Broker) |
Tel: +44 (0)20 3470 0470 | |
David Hignell / Jen Clarke (Corporate Finance) |
| |
Vadim Alexandre (Corporate Broking) |
| |
|
| |
Oberon Capital (Joint Broker) |
Tel: +44 (0)20 3179 5300 | |
Mike Seabrook / Heena Karani |
| |
|
| |
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or renalytix@walbrookpr.com | |
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
About kidneyintelX.dkd and RenalytixTM (www.kidneyintelx.com and www.renalytix.com)
RenalytixTM (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company dedicated to optimizing kidney disease management through precision-based care intervention. Its KidneyIntelX™ technology and data-driven insights help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. This enables clinicians to focus resources and guideline-recommended treatment, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.
Unrecognized and uncontrolled diabetic kidney disease remains one of the largest barriers to reducing suffering and controlling cost in the United States and United Kingdom medical systems, affecting approximately 15 million and 8 million people, respectively.
RenalytixTM has been granted FDA authorization and Medicare reimbursement for kidneyintelX.dkd which is offered commercially throughout the United States. For more information about the kidneyintelX.dkd test, visit www.kidneyintelx.com.